Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma.

ABSTRACT:

Purpose

Previously identified transcriptomic signatures have been based on primary and metastatic melanomas with relatively few American Joint Committee on Cancer (AJCC) stage I tumors, given difficulties in sampling small tumors. The advent of adjuvant therapies has highlighted the need for better prognostic and predictive biomarkers, especially for AJCC stage I and stage II disease.

Experimental design

A total of 687 primary melanoma transcriptomes were generated from the Leeds Melanoma Cohort (LMC). The prognostic value of existing signatures across all the AJCC stages was tested. Unsupervised clustering was performed, and the prognostic value of the resultant signature was compared with that of sentinel node biopsy (SNB) and tested as a biomarker in three published immun

SUBMITTER: Thakur R 

PROVIDER: S-EPMC7617074 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature